ALEX BERENSON: Trump's marijuana order pushes a dangerous lie about drugs

Speaking at AmericaFest 2025, the author criticized recent federal action to reschedule cannabis and argued that legalization and normalization will increase use, addiction and public-health externalities. The piece frames Trump's rescheduling decision as likely to expand accessibility and industry opportunities while raising legal, regulatory and reputational risks and prompting possible enforcement and social-cost responses that could create political backlash and regulatory uncertainty for cannabis and related pharmaceutical markets.

Analysis

Market structure: Federal rescheduling of cannabis is a net demand catalyst for licensed MSOs, cannabis-focused REITs (IIPR) and ancillary suppliers (SMG) as banking access and legitimization lower cost of capital and enable M&A. Expect a near-term equity re-rating: 15–30% upside for large-cap MSOs/REITs within 3–6 months if implementing guidance is released within 60 days; wholesale biomass prices could decline 20–40% as supply responds over 6–12 months, pressuring margins for smaller operators.

Risk assessment: Tail risks include a political/regulatory backlash (state-level excise hikes, advertising bans, renewed criminal enforcement) or continued 280E tax treatment — either can compress EBITDA by 500–1,500 bps. Time horizons matter: immediate (days) volatility around DEA guidance, short-term (weeks–months) liquidity squeezes and oversupply, long-term (years) consolidation benefiting vertically integrated, cash-flow positive operators.

Trade implications: Favor cash-flow and real-estate plays vs levered retail operators. Optionable strategies: buy-call spreads on IIPR/TLRY to capture 20–35% asymmetry while capping premium; short high-debt MSOs (CURLF/CRLBF) for 3–9 months to profit from margin pressure and rollover risk. Key catalysts: DEA/DOJ rule publication (30–60 days), bank guidance on custodial services (60–120 days), potential 280E legislative relief (6–12 months).

Contrarian angles: Consensus underestimates supply-side shock and tax/regulatory friction — positive headlines may be traded as durable wins but profit pools can evaporate via excise taxes and advertising limits. Historical parallels: post-prohibition alcohol industry consolidated; expect similar winner-takes-most in 2–4 years. Mispricings: IIPR (stable rents) likely underpriced vs high-vol volatility MSOs; be wary of names priced for idealized national rollouts.

Key Decisions for Investors

• Establish a 1–1.5% portfolio long in Innovative Industrial Properties (IIPR) via equity or a 6–9 month 20%/40% OTM call spread; target 20–30% upside within 3–6 months if DEA guidance is published within 60 days; set stop-loss at -15% absolute or cut if guidance delayed beyond 90 days.
• Initiate a 1% long in Green Thumb Industries (GTBIF) paired with a 1% short in Curaleaf (CURLF) for 3–9 months to play quality/balance-sheet dispersion; add to long if GTBIF underperforms by >10% on headline volatility and close short if CURLF deleverages or posts margin improvement >400 bps.
• Buy a 3–6 month call spread on Tilray (TLRY) (e.g., 25%/45% OTM) sized to 0.5–1% portfolio exposure to capture upside from cross-border and branded beverage opportunities if banking/access improves; cap premium to <1% of portfolio and exit on 30–40% realized profit or 90 days.
• Reduce direct exposure to single-name alcohol incumbents (e.g., trim BUD/STZ by 0.5–1%) and reallocate to cannabis real-estate/ancillary exposure if federal guidance arrives within 60 days; reverse trimming only if sequential US consumption data shows <2% share shift over 12 months.